CASE OF IATROGENIC CUSHING’S SYNDROME BY TOPICAL TRIAMCINOLONE

Authors

  • Ahsan Zil-E-Ali Fatima Memorial Hospital, Lahore
  • Omer Hanif Janjua Layton Rahmatullah Benevolent Trust Hospital, Lahore
  • Aiza Latif Shaikh Zayed Hospital, Lahore.
  • Muhammad Aadil Rush University, Chicago, Illinois.

Abstract

Cushing’s syndrome is a collection of signs and symptoms due to hypercortisolism. Prolong use of topical steroid may cause this syndrome and suppression of hypothalamic and pituitary function, however such events are more common with oral and parenteral route. There are very few cases of Cushing’s syndrome with a topical application amongst which triamcinolone is the rarest drug. We report a case of 11-year-old boy is presented who developed Cushing’s disease by topical application. The child had body rashes for which the caregiver consulted a local quack, a topical cream of triamcinolone was prescribed. After application for three months, the patient became obese and developed a moon-like face. A thorough biochemical workup and diagnostic test for Cushing’s disease was done to confirm. The following case report a dramatic example of development of the syndrome from chronic topical application of the least potent corticosteroidKeywords:  Triamcinolone; Cushing Syndrome; Endocrinology

Author Biography

Ahsan Zil-E-Ali, Fatima Memorial Hospital, Lahore

Department of Surgery

References

CDC. Growth Charts - Data Table of Infant Head Circumference-for-age Charts [Internet]. [cited 2016 Dec 4]. Available from: https://www.cdc.gov/growthcharts/html_charts/hcageinf.htm

NIH. How many people are affected by or at risk for Cushing’s syndrome? [Internet]. Eunice Kennedy Shriver National Institute of Child Health and Human Development. [cited 2016 Dec 4]. Available from: https://www.nichd.nih.gov/health/topics/cushing/conditioninfo/pages/risk.aspx

NIH. Cushing’s Syndrome. [Internet]. National Institute of Diabetes Digestive and Kidney Diseases. [cited 2016 Dec 4]. Available from: https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome#1

WHO. Model Prescribing Information: Drugs Used in Skin Diseases: Annex: Classification of topical corticosteroids [Internet]. [cited 2016 Dec 4]. Available from: http://apps.who.int/medicinedocs/en/d/Jh2918e/32.html

Siklar Z, Bostanci I, Atli O, Dallar Y. An infantile Cushing syndrome due to misuse of topical steroid. Pediatr Dermatol 2004;21(5):561–3.

De Souza A, Strober BE. Principles of topical therapy. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al., editors. Fitzpatrick's Dermatology in General Medicine. 6th ed. New York: Mc Graw-Hill; 2008. p.2643–51.

Tempark T, Phatarakijnirund V, Chatproedprai S, Watcharasindhu S, Suporsilchai V, Wananukul S. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine. 2010;38(3):328–34.

Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol 2014;59(5):460–4.

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54(1):1–15.

Curtis JA, Cormode E, Laski B, Toole J, Howard N. Endocrine complications of topical and intralesional corticosteroid therapy. Arch Dis Child 1982;57(3):204–7.

Downloads

Published

2018-02-13